abstract |
The present invention relates to FGF-R4 receptor-specific antagonist molecules capable of inhibiting the activity of the FGF-R4 receptor. The antagonist is in particular an FGF-R4-specific antibody capable of inhibiting the activity of the receptor. The invention also relates to the therapeutic use of said antibody, in particular in the field of angiogenesis and in the treatment of certain types of cancer. |